Molecular determinants involved in the allosteric control of agonist affinity in the GABAB receptor by the GABAB2 subunit
Jianfeng Liu (IGF), Damien Maurel (IGF), S\'ebastien Etzol (IGF),, Isabelle Brabet (IGF), Herv\'e Ansanay, Jean-Philippe Pin (IGF), Philippe, Rondard (IGF)

TL;DR
This study uncovers how the GABAB2 subunit's Venus flytrap domain regulates agonist affinity in the GABAB receptor by modulating domain interactions, revealing new insights into receptor allosteric control mechanisms.
Contribution
It demonstrates that the GABAB2 VFT domain directly influences GABAB1 agonist affinity and prevents inhibitory domain interactions, providing a novel understanding of allosteric regulation in GABAB receptors.
Findings
GABAB2 VFT forms hetero-oligomers with GABAB1 VFT.
GABAB2 VFT increases GABAB1 agonist affinity.
GABAB2 VFT prevents inhibitory VFT-HD interactions in GABAB1.
Abstract
The gamma-aminobutyric acid type B (GABAB) receptor is an allosteric complex made of two subunits, GABAB1 (GB1) and GABAB2 (GB2). Both subunits are composed of an extracellular Venus flytrap domain (VFT) and a heptahelical domain (HD). GB1 binds GABA, and GB2 plays a major role in G-protein activation as well as in the high agonist affinity state of GB1. How agonist affinity in GB1 is regulated in the receptor remains unknown. Here, we demonstrate that GB2 VFT is a major molecular determinant involved in this control. We show that isolated versions of GB1 and GB2 VFTs in the absence of the HD and C-terminal tail can form hetero-oligomers as shown by time-resolved fluorescence resonance energy transfer (based on HTRF technology). GB2 VFT and its association with GB1 VFT controlled agonist affinity in GB1 in two ways. First, GB2 VFT exerted a direct action on GB1 VFT, as it slightly…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
